RT Journal Article
SR Electronic
T1 Effects of an urban sanitation intervention on childhood enteric infection and diarrhoea in Mozambique
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.20.20178608
DO 10.1101/2020.08.20.20178608
A1 Jackie Knee
A1 Trent Sumner
A1 Zaida Adriano
A1 Claire Anderson
A1 Farran Bush
A1 Drew Capone
A1 Veronica Casmo
A1 David Holcomb
A1 Pete Kolsky
A1 Amy Macdougall
A1 Evgeniya Molotkova
A1 Judite Monteiro Braga
A1 Celina Russo
A1 Wolf Peter Schmidt
A1 Jill Stewart
A1 Winnie Zambrana
A1 Valentina Zuin
A1 Rassul Nalá
A1 Oliver Cumming
A1 Joe Brown
YR 2020
UL http://medrxiv.org/content/early/2020/08/23/2020.08.20.20178608.abstract
AB Background Onsite sanitation serves more than 740 million people in urban areas, primarily in low-income countries. Although this critical infrastructure may play an important role in controlling enteric infections in high-burden settings, its health impacts have never been evaluated in a controlled trial.Methods We conducted a controlled before and after trial to evaluate the impact an onsite urban sanitation intervention on the prevalence of bacterial and protozoan infection (primary outcome), soil-transmitted helminth (STH) re-infection, and seven-day period prevalence of diarrhoea among children living in informal neighborhoods of Maputo, Mozambique. A non-governmental organization replaced existing shared latrines in poor condition with engineered pour-flush toilets with septic tanks serving household clusters. We enrolled children aged 1-48 months at baseline and measured outcomes before the intervention and at 12 and 24 months following intervention. We measured outcomes concurrently among children served by the sanitation improvements and those in a comparable control arm served by existing poor sanitation. The trial was registered at http://ClinicalTrials.gov, number NCT02362932.Findings At baseline, we enrolled 454 children from 208 intervention clusters and 533 children from 287 control clusters. We enrolled or re-visited 462 intervention and 477 control children 12 months after intervention and 502 intervention and 499 control children 24 months after intervention. Despite nearly exclusive use of the intervention, we found no evidence that engineered onsite sanitation affected the overall prevalence of any measured bacterial or protozoan infection (12-month adjusted prevalence ratio 1·05, 95% CI [0·95-1·16]; 24-month adjusted prevalence ratio 0·99, 95% CI [0·91-1·09]), any STH re-infection (1·11 [0·89-1·38]; 0·95 [0·77-1·17]), or diarrhoea (1·69 [0·89-3·21]; 0·84 [0·47-1·51]) after 12 or 24 months of exposure. Among children born into study sites after the intervention and measured at the 24-month visit, we observed a reduced prevalence of any STH re-infection of 49% (adjusted prevalence ratio 0·51 [95% confidence interval 0·27 - 0·95]), Trichuris of 76% (0·24 [0·10 - 0·60]), and Shigella infection by 51% (0·49 [0·28-0·85]) relative to the same age group at baseline.Interpretation The intervention did not reduce the overall prevalence of enteric infection and diarrhoea among all enrolled children but may have substantially reduced the prevalence of STHs and Shigella among children born into clusters with sanitary improvements.Funding United States Agency for International Development and the Bill & Melinda Gates Foundation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02362932Clinical Protocols https://bmjopen.bmj.com/content/5/6/e008215 Funding StatementThis study was funded by the United States Agency for International Development (www.usaid.gov) under Translating Research into Action (Cooperative Agreement No. GHS-A-00-09-00015-00) and the Bill and Melinda Gates Foundation (www.gatesfoundation.org) grant OPP1137224. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors had full access to all study data and the corresponding author and guarantor had the final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Comite Nacional de Bioetica para a Saude (CNBS), Ministerio da Saude (333/CNBS/14), the Research Ethics Committee of the London School of Hygiene & Tropical Medicine (reference # 8345), and the Institutional Review Board of the Georgia Institute of Technology (protocol # H15160).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified participant data which underlie the results reported in this manuscript will be made available beginning three months after publication of the peer-reviewed manuscript. A corresponding data dictionary, the study protocol, and analysis plan and code will also be available for the stated period. Data will be available to researchers who provide a methodologically sound proposal. Proposals for data use can be submitted to joebrown@unc.edu and authors of approved proposals will need to sign a data access agreement. Once approved, requestors will be able to access data on the MapSan trial Open Science Forum website (https://osf.io/p5shk). The published trial protocol be accessed at: https://bmjopen.bmj.com/content/5/6/e008215. https://osf.io/p5shk